ArticlePharmacoEconomics2024

Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.

Shih-Wen Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.